Adoption of PCSK9 Inhibitors Among Patients With Atherosclerotic Disease

BACKGROUND: PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitors represent a promising class of lipid‐lowering therapy, although their use has been limited by cost concerns. METHODS AND RESULTS: A retrospective cohort study was conducted using a nationwide commercial claims database comp...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Am Heart Assoc
Autors principals: Dayoub, Elias J., Eberly, Lauren A., Nathan, Ashwin S., Khatana, Sameed Ahmed M., Adusumalli, Srinath, Navar, Ann Marie, Giri, Jay, Groeneveld, Peter W.
Format: Artigo
Idioma:Inglês
Publicat: John Wiley and Sons Inc. 2021
Matèries:
Original Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC8200752/
https://ncbi.nlm.nih.gov/pubmed/33904340
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1161/JAHA.120.019331
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars